Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The corneal stromal collagen and extracellular matrix (ECM) proteins constitute approximately 90% of the corneal thickness and are fundamental to the eye's structural integrity and optical transparency (Meek & Knupp, 2015). This matrix is primarily composed of highly organized Type I and Type V collagen fibrils arranged in orthogonal lamellae, stabilized by small leucine-rich proteoglycans such as lumican and keratocan (Sridhar, 2018). Pathological alterations in this ECM, such as those seen in keratoconus or corneal ectasia, lead to biomechanical weakening, corneal thinning, and significant visual impairment (StatPearls, 2023). Therapeutic strategies targeting these proteins include corneal collagen cross-linking (CXL) using riboflavin and UV-A light to induce covalent bonds between collagen fibers, thereby increasing stromal rigidity (AAO, 2023). Pharmacological agents like Losartan are also being investigated to modulate the fibrotic response by inhibiting TGF-beta signaling, which prevents the formation of disorganized ECM and scarring (Wilson et al., 2022). Furthermore, mitomycin C is frequently used during refractive surgery to inhibit the proliferation of myofibroblasts that produce excessive ECM, reducing the risk of post-operative haze (PubMed, 2021). Regenerative medicine approaches are also emerging, utilizing recombinant collagen scaffolds to restore the stromal architecture in cases of severe thinning (Fagerholm et al., 2014). Overall, the corneal ECM serves as both a structural scaffold and a dynamic signaling environment that is critical for maintaining the cornea's refractive function and health.
Photo-oxidative cross-linking of collagen fibers to increase biomechanical stability; inhibition of TGF-beta signaling to reduce myofibroblast-mediated scarring; structural replacement or augmentation of the ECM network; inhibition of fibroblast proliferation to prevent excessive ECM deposition.
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Corneal stromal collagen and extracellular matrix proteins.